Department of Orthopedic Surgery, Chung-Ang University Gwangmyeong Hospital, Chung-Ang University College of Medicine, Seoul 06911, Republic of Korea.
Department of Orthopedic Surgery, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul 06973, Republic of Korea.
Medicina (Kaunas). 2023 Jan 11;59(1):148. doi: 10.3390/medicina59010148.
: Although the effects of cartilage repair in patients who are undergoing high tibial osteotomy (HTO) remains controversial, cartilage repair may be required for the full-thickness cartilage defect because of a concern of lower clinical outcome. The purpose of this study was to investigate clinical outcome and cartilage repair following implantation of allogeneic umbilical cord-blood-derived MSCs (UCB-MSCs)-hyaluronate composite in patients who received HTO for medial knee osteoarthritis (OA) with full-thickness cartilage defect. : Inclusion criteria were patients with a medial knee OA, a full-thickness cartilage defect (International Cartilage Repair Society (ICRS) grade IV) ≥ 3 cm of the medial femoral condyle, and a varus deformity ≥ 5°. The full-thickness cartilage defect was treated with implantation of an allogeneic UCB-MSCs-hyaluronate composite following medial open-wedge HTO. Visual analogue scale for pain and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score were assessed at each follow-up. Cartilage repair was assessed by the ICRS cartilage repair assessment system at second-look arthroscopy when the plate was removed. : Twelve patients (mean age 56.1 years; mean defect size: 4.5 cm) were included, and 10 patients underwent second-look arthroscopy during plate removal after a minimum of 1 year after the HTO. At the final follow-up of mean 2.9 years (range; 1-6 years), all clinical outcomes had improved. At second-look arthroscopy, repaired tissue was observed in all cases. One case (10%) showed grade I, seven (70%) cases showed grade II, and two (20%) cases showed grade III according to ICRS cartilage repair assessment system, which meant that 80% showed an overall repair assessment of "normal" or "nearly normal". : Allogeneic UCB-MSCs-HA composite implantation combined with HTO resulted in favorable clinical outcome and cartilage repair in all cases. These findings suggest that UCB-MSCs-HA composite implantation combined with HTO would be a good therapeutic option for patients with knee OA and full-thickness cartilage defects.
异体脐带血源性间充质干细胞(UCB-MSCs)-透明质酸钠复合移植治疗全层软骨缺损合并内侧间室骨关节炎行胫骨高位截骨术后的临床疗效及软骨修复:虽然软骨修复在接受胫骨高位截骨术(HTO)的患者中的效果仍存在争议,但由于担心临床疗效降低,对于全层软骨缺损,可能需要进行软骨修复。本研究旨在探讨异体脐带血源性间充质干细胞(UCB-MSCs)-透明质酸钠复合移植治疗全层软骨缺损合并内侧间室骨关节炎行胫骨高位截骨术后的临床疗效和软骨修复。
内侧膝关节骨关节炎患者、内侧股骨髁全层软骨缺损(国际软骨修复学会(ICRS)分级 IV)≥3cm、内翻畸形≥5°。采用内侧开放楔形 HTO 结合异体 UCB-MSCs-透明质酸钠复合移植治疗全层软骨缺损。在每次随访时,采用视觉模拟评分(VAS)和西部安大略省和麦克马斯特大学骨关节炎指数(WOMAC)评分评估疼痛。在取出钢板后,通过二次关节镜检查,采用 ICRS 软骨修复评估系统评估软骨修复情况。
共纳入 12 例患者(平均年龄 56.1 岁;平均缺损大小 4.5cm),10 例患者在 HTO 后至少 1 年取出钢板时行二次关节镜检查。在平均 2.9 年(1-6 年)的最终随访时,所有临床结果均得到改善。在二次关节镜检查中,所有病例均观察到修复组织。根据 ICRS 软骨修复评估系统,1 例(10%)为 I 级,7 例(70%)为 II 级,2 例(20%)为 III 级,这意味着 80%的病例总体修复评估为“正常”或“接近正常”。
异体 UCB-MSCs-HA 复合移植联合 HTO 治疗全层软骨缺损合并内侧间室骨关节炎,所有患者均获得良好的临床疗效和软骨修复。这些发现表明,UCB-MSCs-HA 复合移植联合 HTO 可能是治疗全层软骨缺损合并膝关节骨关节炎患者的一种较好的治疗选择。